LYEL
NASDAQ · Biotechnology
Lyell Immunopharma Inc
$14.86
-0.14 (-0.93%)
Open$15.75
Previous Close$15.00
Day High$16.08
Day Low$14.75
52W High$45.00
52W Low$7.20
Volume—
Avg Volume267.5K
Market Cap364.15M
P/E Ratio—
EPS$-12.01
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+88.1% upside
Current
$14.86
$14.86
Target
$27.95
$27.95
$18.45
$27.95 avg
$35.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 51.0K | 677.9K | 107.82M |
| Net Income | -389,787,161 | -4,665,005,916 | -16,079,673 |
| Profit Margin | -762,355.6% | -724,237.8% | -14.9% |
| EBITDA | -366,234,172 | -4,626,628,502 | -19,078,562 |
| Free Cash Flow | — | — | -8,704,547 |
| Rev Growth | -92.5% | -92.5% | +2.1% |
| Debt/Equity | — | — | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |